From the field - Oxymoron no more: The potential of nonprofit drug companies to deliver on the promise of medicines for the developing world

Health Affairs

Volumn 24, Issue 4, 2005, Pages 1057-1063

  Hale, Victoria G ^a   Woo, Katherine ^a   Lipton, Helene Levens ^a  

^a Institute for OneWorld Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESSENTIAL DRUG;

ARTICLE; DEVELOPING COUNTRY; DRUG INDUSTRY; ENDEMIC DISEASE; ETHICS; HEALTH CARE DELIVERY; HUMAN; INTERNATIONAL COOPERATION; NON PROFIT ORGANIZATION; NONBIOLOGICAL MODEL; ORGANIZATION; ORGANIZATION AND MANAGEMENT; POVERTY; PUBLIC HEALTH SERVICE; PUBLIC RELATIONS; SOCIAL BEHAVIOR;

DEVELOPING COUNTRIES; DRUG INDUSTRY; DRUGS, ESSENTIAL; ENDEMIC DISEASES; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERINSTITUTIONAL RELATIONS; INTERNATIONAL COOPERATION; MODELS, ORGANIZATIONAL; ORGANIZATIONAL INNOVATION; ORGANIZATIONS, NONPROFIT; POVERTY; PRIVATE SECTOR; PUBLIC HEALTH ADMINISTRATION; SOCIAL RESPONSIBILITY;

EID: 23044507037     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.24.4.1057     Document Type: Article

References (36)

1. World Health Organization, WHO Medicines Strategy: Countries at the Core, 2004-2007, www.who.int/medicines/strategy/MedcinesStrategy2004_2007/ MedcinesStrategy2004_7English.pdf (5 May 2005).
2. Essential medicines satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. See WHO, "Guidelines for Drug Donations: What Are Essential Medicines?" 2004, www.who.int/medicines (26 April 2004).
3. Médecins sans Frontières, "The Campaign: What Is the Campaign?" www.accessmed-msf.org/campaign/campaign.shtm (26 April 2005).
4. C.K. Prahalad, The Fortune at the Bottom of the Pyramid (Upper Saddle River, N.J.: Wharton School Publishing, 2005).
5. P. Trouiller et al., "Drug Development for Neglected Diseases: A Deficient Market and a Public-Health Policy Failure," Lancet 359, no. 9324 (2002): 2188-2194.
6. OneWorld Health, "The Global Burden of Infectious Disease," 2004, www.oneworldhealth.org/global/global_burden.php?PHPSESSID=3c651b 5d920c393a9519009912f28bb0 (26 April 2005).
7. MSF, "The Campaign."
8. Merck, "The Story of Mectizan," www.merck.com/about/cr/ mectizan/home.html (4 April 2005).
9. GSK, "Lymphatic Filariasis Programme," www.gsk.com/filariasis/ index.htm (4 April 2005).
10. Boehringer-Ingelheim, "Viramune MTCT Donation Programme," 5 December 2004, www.boehringer-ingelheim.com/corporate/news/photo_mtct.htm (4 April 2005).
11. S. Nwaka and R.G. Ridley, "Virtual Drug Discovery and Development for Neglected Diseases through Public-Private Partnerships," Nature Reviews: Drug Discovery 2, no. 11 (2003): 919-928;
12. M. Reich, ed., Public-Private Partnerships for Public Health, April 2002, www.hsph.harvard.edu/hcpds/partnerbook/Partnershipsbook.PDF (4 April 2005);
13. and R. Widdus and K. White, Combating Diseases Associated with Poverty: Financing Strategies for Product Development and Potential Role of Public-Private Partnerships (Geneva: Initiative on Public-Private Partnerships for Health, 2004).
14. K. Caines et al., Impact of Public-Private Partnerships Addressing Access to Pharmaceuticals in Low-Income Countries: Uganda Pilot Study, Initiative on Public-Private Partnerships for Health (Geneva: IPPPH, October 2003).
15. Nwaka and Ridley, "Virtual Drug Discovery";
16. and Reich, ed., Public-Private Partnerships.
17. Rockefeller Foundation, Partnering to Develop New Products for Diseases of Poverty: One Donor's Perspective (New York: Rockefeller Foundation, 2004).
18. Global Alliance for TB, www.tballiance.org;
19. International AIDS Vaccine Initiative, www.iavi.org;
20. Malaria Vaccine Initiative, www.malariavaccine.org;
21. and Medicines for Malaria Venture, www.mmv.org.
22. See Nwaka and Ridley, "Virtual Drug Discovery";
23. and Widdus and White, Combating Diseases.
24. P.L. Alonso et al., "Efficacy of the RTS,S/AS02A Vaccine against Plasmodium falciparum Infection and Disease in Young African Children: Randomised Controlled Trial," Lancet 364, no. 9443 (2004): 1411-1420.
25. Medicines for Malaria Venture, www.mmv.org.
26. See the Institute for OneWorld Health home page, www.oneworldhealth.org.
27. CMS, "Health Care Industry Market Update: Pharmaceuticals," 10 January 2003, www.cms.hhs.gov/reports/hcimu/hcimu_01102003.pdf (26 April 2005);
28. and Families USA, Profiting from Pain: Where Prescription Drug Dollars Go, July 2002, www.familiesusa.org/site/DocServer/PPreport.pdf?docID=249 (26 April 2005).
29. C. Nathan, "Antibiotics at the Crossroads," Nature 431, no. 7011 (2004): 899-902.
30. A. Rassi Jr., A. Rassi, and W.C. Little, "Chagas' Heart Disease," Clinical Cardiology, December 2000, www.clinicalcardiology.org/ briefs/200012briefs/cc23-883.review.html (28 March 2005).
31. CDC, "Chagas Disease after Organ Transplantation - United States, 2001," Morbidity and Mortality Weekly Report, 15 March 2002, www.cdc.gov/mmwr/preview/mmwrhtml/mm5110a3.htm (28 March 2005).
32. OneWorld Health, "Global Burden."
33. V. Hale and A. Herskowitz, presentation at the Annual Meeting of the American Society of Tropical Medicine and Hygiene, Miami, Florida, 8-10 November 2004.
34. See www.dndi.org.
35. See www.aeras.org.
36. Prahalad, The Fortune.